Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes

OBJECTIVE: To assess the safety and efficacy of dual sodium–glucose cotransporter (SGLT) 1 and SGLT2 inhibition with sotagliflozin as adjunct therapy to insulin in type 1 diabetes. RESEARCH DESIGN AND METHODS: We treated 33 patients with sotagliflozin, an oral dual SGLT1 and SGLT2 inhibitor, or plac...

Full description

Saved in:

Bibliographic Details
Published in:	Diabetes Care
Main Authors:	Sands, Arthur T., Zambrowicz, Brian P., Rosenstock, Julio, Lapuerta, Pablo, Bode, Bruce W., Garg, Satish K., Buse, John B., Banks, Phillip, Heptulla, Rubina, Rendell, Marc, Cefalu, William T., Strumph, Paul
Format:	Artigo
Language:	Inglês
Published:	American Diabetes Association 2015
Subjects:	Diabetes Care Symposium
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4831906/ https://ncbi.nlm.nih.gov/pubmed/26049551 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc14-2806
Tags:	Add Tag No Tags, Be the first to tag this record!

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes

Similar Items